Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application

被引:48
作者
Zhou, Qingyu [1 ]
Gallo, James M. [1 ]
机构
[1] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19140 USA
基金
美国国家卫生研究院;
关键词
Sunitinib; LC-MS/MS; Mouse intracerebral tumor model; Pharmacokinetics; TYROSINE KINASE INHIBITOR; GROWTH-FACTOR; SU11248; METABOLITE;
D O I
10.1016/j.jpba.2009.10.006
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The primary challenge associated with the development of an assay method for the determination of drug concentrations in relatively small amount of mouse plasma and tissue samples is to improve extraction efficiency and detection sensitivity. In this work, a liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based method combined with protein precipitation, liquid-liquid extraction and solid-phase extraction techniques was developed for the determination of sunitinib in mouse plasma, brain tumor and normal brain tissue, respectively. The instrument was operated under the multiple reaction monitoring (MRM) mode using electrospray ionization (ESI) in the positive ion mode. A good linear relationship with coefficients of determination >= 0.99 was achieved over the concentration ranges of 1.37-1000 ng/mL for plasma and 4.12-1000 ng/g for the normal brain and brain tumor. The limits of quantification (LOQs) for sunitinib in mouse plasma, brain tumor and normal brain tissue are 1.37 ng/mL, 4.12 ng/g and 4.12 ng/g, respectively. The reproducibility of the LC-MS/MS method is reliable, with the intra- and inter-day precision being less than 15% and accuracy within +/- 15%. The established method was successfully applied to the characterization of sunitinib disposition in the brain and brain tumor as well as its systemic pharmacokinetics in a murine orthotopic glioma model. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:958 / 964
页数:7
相关论文
共 17 条
[1]  
Abrams TJ, 2003, MOL CANCER THER, V2, P1011
[2]   Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction [J].
Barattè, S ;
Sarati, S ;
Frigerio, E ;
James, CA ;
Ye, C ;
Zhang, Q .
JOURNAL OF CHROMATOGRAPHY A, 2004, 1024 (1-2) :87-94
[3]   A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period [J].
Britten, Carolyn D. ;
Kabbinavar, Fairooz ;
Hecht, J. Randolph ;
Bello, Carlo L. ;
Li, Jim ;
Baum, Charles ;
Slamon, Dennis .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (03) :515-524
[4]   Sunitinib: From rational design to clinical efficacy [J].
Chow, Laura Q. M. ;
Eckhardt, S. Gail .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :884-896
[5]   Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma [J].
de Boueard, Sophie ;
Herlin, Paulette ;
Christensen, James G. ;
Lemoisson, Edwige ;
Gauduchon, Pascal ;
Raymond, Eric ;
Guillamo, Jean-Sebastien .
NEURO-ONCOLOGY, 2007, 9 (04) :412-423
[6]   Molecular basis for sunitinib efficacy and future clinical development [J].
Faivre, Sandrine ;
Demetri, George ;
Sargent, William ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2007, 6 (09) :734-745
[7]   Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry [J].
Haouala, A. ;
Zanolari, B. ;
Rochat, B. ;
Montemurro, M. ;
Zaman, K. ;
Duchosal, M. A. ;
Ris, H. B. ;
Leyvraz, S. ;
Widmer, N. ;
Decosterd, L. A. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (22) :1982-1996
[8]   A Population Pharmacokinetic Meta-analysis of Sunitinib Malate (SU11248) and Its Primary Metabolite (SU12662) in Healthy Volunteers and Oncology Patients [J].
Houk, Brett E. ;
Bello, Carlo L. ;
Kang, Dongwoo ;
Amantea, Michael .
CLINICAL CANCER RESEARCH, 2009, 15 (07) :2497-2506
[9]  
Mendel DB, 2003, CLIN CANCER RES, V9, P327
[10]   Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry [J].
Minkin, Patton ;
Zhao, Ming ;
Chen, Zhaoyuan ;
Ouwerkerk, Jan ;
Gelderblom, Hans ;
Baker, Sharyn D. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 874 (1-2) :84-88